ABBREVIATIONS: MMP-9, matrix metalloproteinase-9; PI3K, phosphatidylinositol 3-kinase; MAPK, mitogen-activated protein kinase.
INTRODUCTION
Gliomas constitute nearly 60% of primary brain tumors and usually infiltrate normal brain parenchyma. Gliomas are categorized as their histologic features, and the major type of gliomas are astrocytomas [1] . Glioblastoma multiforme (GBM) is the most common type of astrocytomas arising in adults and clinically very aggressive [2] . These tumors typically show necrosis and hemorrhage. Patients diagnosed as GBM survive less than 1 year due to diffusely infiltrating nature of GBM. Glioma cells migrate away from the primary tumor site so that surgical resection of a tumor mass is not effective for remission [3] .
Matrix metalloproteinases (MMPs) are critically involved in many physiological and pathological processes such as tissue remodeling and cancer progression [4] . Especially, MMP-2 and MMP-9 (known as gelatinases) have been reported to play crucial roles in tumor angiogenesis and metastasis. It has been also reported that enhanced gelatinase expression in various types of cancers corresponds to increased invasion and metastasis [5] .
Thrombin, a trypsin-like serine protease, is the most copious enzyme participating in the coagulation cascade. In addition to its hemostatic roles, thrombin modulates a diversity of pathophysiological functions such as inflammation, cell migration and proliferation, apoptosis and so on. There are many evidences that thrombin regulates MMP-9 expression [6] [7] [8] and cancer cell migration [9] [10] [11] . Nevertheless, the effect of thrombin on glioma cell migration is not fully understood even though thrombin released by hemorrhagic site of GBM may have a important role in invasion. In the present study, we focused on demonstrating the effects of thrombin on the migration of C6 rat glioma cells, which are morphologically similar to GBM [12] , and possible underlying signaling pathways that thrombin induces MMP-9-mediated migration.
The C6 rat glioma cell line was cultured in Dulbecco's modified Eagle's medium (DMEM; GIBCO BRL, Grand Island, NY, USA) in the presence of 10% fetal bovine serum (FBS; Hyclone Laboratories, Inc.), 100 U/ml of penicillin, 100 mg/ml of streptomycin and 2 mM of glutamine (GIBCO BRL, Grand Island, NY, USA). Cells were maintained at 37 o C in a humidified atmosphere with 5% CO2. All inhibitors were pretreated in serum-deprived culture medium for 1 hr followed by thrombin treatment as indicated.
Cell migration assay
Cell migration assay was performed by BD Falcon TM Cell Culture Inserts (BD Bioscience, Bedford, MA; pore size, 8-μ m) in 24-well culture plates. Cell culture inserts were coated with fibronectin (Sigma, St. Louis, MO, USA; 3μg/ml) both upper and lower surfaces. Approximately 0.7×10 5 cells in 400μl of serum-free medium were seeded in the upper chamber and 400μl of the same medium was placed in the lower chamber. When seeded, cells were respectively pretreated with appropriate concentration of inhibitors; SB203580, SP600125, U0126, and wortmannin. After 1 hr of pretreatment, thrombin was added to the lower chamber and the plates were incubated for 6 hr at 37 o C in 5% CO2 incubator. Subsequently, cells were fixed in 3.7% formaldehyde solution for 10 min and permeabilized by 0.2% Triton X-100 for 10 min. Then, cells on the lower surface were stained with 0.2% crystal violet and rinsed with PBS several times. Non-migrating cells in the upper chamber were attentively removed by cotton swabs. The migrating cells were counted by light microscopy.
Western blot analysis
After removed the culture media, the C6 rat glioma cells were harvested and lysed with PRO-PREP TM Protein Extraction Solution (iNtRON Biotechnology, Inc.). The obtained protein samples were quantified by the BCA protein assay and the same amounts of total cellular proteins were resolved on 10% SDS-polyacrylamide gels. After SDS-PAGE, proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Amersham Biosciences, Piscataway, NJ, USA). The membranes were incubated in blocking solution (5% skim milk in TBST) for 1 hr at room temperature and then probed overnight with suitable antibodies at 4 o C; anti-MMP-9 (Affinity BioReagents, Golden, CO, USA; 1 : 1,000), p-Akt, Akt (Cell Signaling Technology, Inc.; 1 : 1,000), or β-actin (Sigma-Aldrich, St. Louis, MO, USA; 1 : 5,000). After three washes with TBST, the membranes were incubated with either horseradish peroxidase (HRP)-conjugated goat anti-rabbit or donkey anti-mouse secondary antibody (Jackson ImmunoResearch) for 2 hr at room temperature. The blots were detected by enhanced chemiluminescence using Kodak Ⓡ BioMax TM XAR Film.
RNA isolation and semi-quantitative RT-PCR analysis
Isolation of total cellular RNA from C6 glioma cells was performed using the Total RNA Extraction Kit (iNtRON Biotechnology, Inc.) according to the manufacturer's instructions. Total RNA was quantified by NanoDrop spec- 
Gelatin zymography
The gelatin zymography was carried out in 8% polyacrylamide gels containing 1 mg/ml of gelatin. C6 glioma cells were plated in 60 mm culture dishes and incubated overnight in serum-free medium. Cell culture supernatants were collected and concentrated by Amicon Ⓡ Ultra Centrifugal Filter (Millipore, Bedford, MA) subsequent to 24 hr-thrombin treatment. These samples were mixed with non-reducing 5x loading buffer without heating and electrophoresed on the gel as mentioned above. After PAGE, gels were thoroughly washed with enzyme renaturing buffer (2.5% Triton X-100 solution) at room temperature for 4 times every 15 min. The gels were then transferred into incubation buffer (50 mM Tris-HCl, 0.15 M NaCl, 10 mM CaCl2, and 0.02% NaN3) and placed in a 37 o C shaking incubator for 24 hr followed by Coomassie brilliant blue R-250 staining and destaining procedures.
Statistical analysis
All data are expressed as the mean±standard deviation (SD). Statistical significance was analyzed by two-tailed Student's t-test. Data with values of p＜0.05 were considered as statistically significant. Single (* and #) and double (** and ##) marks represent statistical significance in p ＜0.05 and p＜0.01, respectively.
RESULTS

Thrombin induced the migration of C6 glioma cells
In the previous studies, it has been demonstrated that thrombin induces cell motility in many cell lines [9, 13, 14] . To investigate the effect of thrombin on the migration of C6 glioma cells, we used the Boyden chamber migration assay. Approximately 0.7×10 5 cells were plated in the upper chamber of cell culture inserts and incubated with or without 25 U/ml of thrombin. After 6 hr of incubation, the cells migrating through the membrane toward thrombin containing serum-free media were stained with crystal violet and the number of migrated cells was counted (Fig. 1) . The number of migrated cells was significantly increased in the presence of thrombin compared to control, suggesting that thrombin has a chemotactic effect on C6 glioma cells. 
M APK inhibitors had an inhibitory effect on thrombin-induced migration of C6 glioma cells
Involvement of MAPK pathway in the regulation of cancer cell migration has been investigated by many studies [15] [16] [17] . In the present study, to determine the underlying mechanism for chemotactic action of thrombin, C6 cells were treated with some MAPK pathway inhibitors: SB203580 (20μM), a specific inhibitor of p38-MAPK; SP600125 (20μM), a selective inhibitor of c-Jun N-terminal kinase (JNK); U0126 (10μM), a selective inhibitor of MEK/ERK. All inhibitors were pretreated for 1 hr in serum free media with indicated concentrations and thrombin was subsequently treated for 6 hr. As shown in Fig. 2 , thrombin-induced migrating cells were reduced with pretreatment of the MAPK inhibitors. Inhibition of p38 with SB203580 showed significant inhibition of C6 migration (Fig. 2) . Especially, inhibition of JNK and ERK with SP600125 and U0126, respectively, exerted such a strong inhibition that the number of migrated cells was reduced almost to control level (Fig. 2) . These results suggest that MAPK pathway may regulate thrombin-induced migration of C6 glioma cells. 
Thrombin-induced C6 cell migration was significantly increased with wortmannin, a PI3K inhibitor
The previous studies have been shown that PI3K pathway is also related to the cancer cell motility [18, 19] . On this account, we investigated the effect of the PI3K pathway on thrombin-induced C6 cell migration with a PI3K inhibitor wortmannin, an antifungal antibiotic. 100 nM of wortmannin was used for migration assay and other experimental procedures were the same as mentioned above.
Wortmannin significantly potentiated the migratory activity induced by thrombin (Fig. 3) . This result may suggest that the PI3K pathway negatively regulates thrombin-induced C6 cell migration.
MMP-9 expression was correlated with C6 cell migration propensity
To elucidate whether the thrombin-induced migration and MMP-9 expression are directly related, we used an MMP-9 inhibitor (MMPI), batimastat, for migration assay. Quantitative analysis of migration assay. The cell migration was quantified by counting the cells that migrating through the membranes. All data were obtained from three independent experiments and presented as the means±SD. **p＜0.01 and # p＜0.05 indicate statistically signficant difference between control and thrombin, and thrombin and MMPI thrombin, respectively.
Fig. 5.
Effects of thrombin and MAPK or PI3K inhibitors treatment on MMP-9 expression in mRNA level. C6 cells were pretreated with inhibitors for 1 hr, followed by thrombin (5 U/ml) treatment for 4 hr. Subsequently, RNA samples were isolated and subjected to semi-quantitative RT-PCR for MMP-9 with a housekeeping gene, GAPDH, as an internal control. MMP-9 mRNA expression patterns were similar to western blot and zymographic data.
The suppressive effect of MMPI is represented in Fig. 6 . It clearly showed that MMP-9 is directly involved in cell migration stimulated by thrombin.
To determine whether MMP-9 is regulated by MAPK and PI3K pathways in the thrombin-induced migration of C6 glioma cells, we examined the changes of MMP-9 expression in multiple stages such as mRNA, protein, and extracellular levels. C6 cells were pre-incubated with the MAPK or PI3K inhibitors for 1 hr and thrombin was subsequently treated for 24 hr in serum-free media. After incubation, the conditioned media were collected and concentrated for zymography and the cells were harvested and lysed for western blot analysis. Gelatinolytic activities of MMP-9 were visualized by zymography. As shown in Fig.  4A , thrombin induces MMP-9 secretion and it is suppressed by MAPK inhibitors whereas thrombin-induced MMP-9 secretion was potently increased by wortmannin (Fig. 4A) . These results closely correspond to migration assay data. Western blot analysis also presented the same tendency to zymographic data. To further confirm, we measured MMP-9 expression in mRNA level using semi-quantitative RT-PCR assay. After pretreated the inhibitors for 1 hr, C6 cells were incubated with thrombin for 4 hr. MMP-9 mRNA was expressed in the same manner as MMP-9 protein expression (Fig. 5) . These data strongly support that thrombin-mediated MMP-9 expression is regulated by MAPK and PI3K pathways.
DISCUSSION
Glioblastoma multiforme (GBM) is one of the most aggressive CNS tumors with very poor prognosis because of its highly-infiltrative nature [20] . GBM has a histologically characteristic feature which forms a serpentine pattern of necrosis and vascular or endothelial cell proliferation. These necrotic lesions often contain hemorrhagic components [2] . These conditions lead glioma cells to have more chances of exposure to thrombin. Previous studies have been revealed that thrombin is involved in cancer cell migration and invasion [9, 10, 21] . In the present study, we found that thrombin enhances migration of C6 rat glioma cells by Boyden chamber migration assay.
To determine the mechanism of the thrombin effect, we considered MAPK and PI3K pathways as pivotal factors based on the former studies [22, 23] . Thrombin-induced migratory ability was significantly blocked by MAPK inhibitors. Wortmannin, a specific inhibitor of the PI3K pathway, on the other hand, surprisingly reinforced the thrombin-mediated cell migration. We used 100 nM and 1μM of wortmannin for migration assay, but 1μM was less potent than 100 nM of wortmannin in inducing migratory ability (data not shown). These results might be caused by excessive PI3K pathway inhibition in 1μM of wortmannin treatment. Because PI3K pathway is critical in cell survival, its inordinate suppression subjects to cellular damage. The C6 cells treated with 1μM of wortmannin presented slight morphological changes and with 10μM showed more severe changes in migration assay.
As MMPs are key components of cell migration and invasion [5, 24] , we investigated the relationship between C6 cell migration and MMP-9. Thrombin-induced migration was effectively suppressed by an MMP-9 inhibitor, batimastat. It supports that MMP-9 is directly involved in cell migration stimulated by thrombin. However, batimastat alone could not totally block the thrombin-induced migration. This implies that there are more factors responsible for thrombin-induced cell migration other than MMP-9. Thrombin induced MMP-9 expression in protein and mRNA level, parallel to increase in C6 cell migration. Induced MMP-9 expression was significantly attenuated by MAPK inhibitors and augmented by the PI3K inhibitor. Our results indicate that these pathways regulate thrombin-mediated MMP-9 expression and it affects migratory activity of C6 cells. That is, the activator of PI3K pathway, such as the platelet-derived growth factor (PDGF), or MAPK inhibitors might inhibit the thrombin-induced MMP-9 expression and migration. A previous study actually demonstrated that PDGF inhibits MMP-9 activity in C6 cells [25] . Wortmannin, for itself, did not increase both MMP-9 expression and cell migration (Data not shown).
In conclusion, the present study suggests that thrombin mediates C6 glioma cell migration by increasing expression of MMP-9. In addition, MAPK and PI3K pathways might be involved in thrombin-induced cell migration and MMP-9 expression. The migratory ability of cells is an important factor for cancer metastasis. Together with the previous studies, this study suggests that inhibition of MAPK pathway or potentiation of PI3K pathway could be a valuable therapeutic target for the treatment of metastatic glioblastoma.
